Quality of life in advance stage lung cancer
Recruiting
- Conditions
- ung cancer and quality of lifeLongkanker en kwaliteit van leven
- Registration Number
- NL-OMON22982
- Lead Sponsor
- Medical Center LeeuwardenHenri Dunantweg 28934 AD Leeuwarden
- Brief Summary
one
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
Newly diagnosed stage III or IV lung cancer, both histopathological proven as clinical diagnosis in patients not able to undergo invasive diagnostics.
Exclusion Criteria
First line of cancer treatment for stage III or IV started in another hospital.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) QOL as assessed by questionnaires (QLQ-C30, QLQ-LC13) (sum scores and different subdomains).
- Secondary Outcome Measures
Name Time Method Secondary endpoints<br /><br>2) Treatment satisfaction / decision regret as assessed by questionnaires (CTSQ / DRS) (sum scores and different subdomains).<br /><br>3) Treatment motives as assessed by questionnaire (OPT) (rankings and subdomain scores). <br /><br>4) QOL (QLQ-C30, QLQ-LC13, QODDQ/EuroQ2), treatment satisfaction / decision regret (CTSQ / DRS) and treatment motives (OPT).<br /><br><br /><br>Other study parameters<br /><br>4A. For endpoints 1), 2) and 3), patient and disease characteristics (see parameters under 5.2) will be assessed as potential predictors. <br /><br>4B. For secondary endpoint 2), treatment motives (OPT-score), decision control (CPS), symptom burden (QLQ-LC13), treatment tolerance / efficacy and QOL (QLQ-C30) will be assess as additional potential predictors.<br /><br>4C. For secondary endpoint 3), symptom burden (QLQ-LC13), treatment tolerance / efficacy and quality of life (QLQ-C30, QODDQ/EuroQ2) will be assess as additional potential predictors.<br>